Joey Azofeifa
Seminars
Wednesday 29th October 2025
Orally Bioavailable NRF2 Molecular Glue Degrader Effective in KEAP1-Mutant Cancer
11:30 am
Download the Full Event Guide for Full Session Details.
- Novel HTS Transcriptomics screen identifies initial NRF2 hit
- Hit and Analog induces an interaction between NRF2 and BTrCP
- Optimized analogs lead to significant in vivo activity in multiple lung cancer models with very favorable drug-like and safety profiles
